73.82 <%= Resources.Global.txtDown %>
Updated 15:07:01
Change % -1.52% Stock price decreasing
Change -1.14 Stock price decreasing
Volume 127,135
High 74.90
Low 73.72
Open 74.76
ISIN BE0003739530
Prev close 74.96
# of shares 194.51M
Market cap 14,358M EUR
Intraday

UCB
Market is open (until 16:30) - Delayed 15 min
 
Price development Latest 1 week 1 month 3 months 6 months 1 year
 
  73.82 -2.7% Stock price decreasing -4.1% Stock price decreasing -5.5% Stock price decreasing 10.5% Stock price increasing 15.3% Stock price increasing
Powered by TradingView

Company profile

UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, both of which have lost patent protection. The firm's newer key drugs include Cimzia (rheumatoid arthritis, psoriatic arthritis, and Crohn's disease), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), and Briviact (epilepsy).

Copyright Berlingske Media 2018  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
17 December 2018 15:22:04
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20181207.1 - EUROWEB7 - 2018-12-17 16:22:04 - 2018-12-17 15:22:04 - 1000 - Website: OKAY